Asunto(s)
Hemorragia Gastrointestinal/etiología , Hemangiosarcoma/complicaciones , Hemangiosarcoma/diagnóstico , Neoplasias Intestinales/complicaciones , Neoplasias Intestinales/diagnóstico , Intestino Delgado , Anciano , Neoplasias Óseas/secundario , Endoscopía Capsular , Diagnóstico Diferencial , Endoscopía Gastrointestinal , Transfusión de Eritrocitos , Humanos , MasculinoRESUMEN
Anti-programmed cell death protein 1 (PD-1) therapy provides long-term clinical benefits to patients with advanced melanoma. The composition of the gut microbiota correlates with anti-PD-1 efficacy in preclinical models and cancer patients. To investigate whether resistance to anti-PD-1 can be overcome by changing the gut microbiota, this clinical trial evaluated the safety and efficacy of responder-derived fecal microbiota transplantation (FMT) together with anti-PD-1 in patients with PD-1-refractory melanoma. This combination was well tolerated, provided clinical benefit in 6 of 15 patients, and induced rapid and durable microbiota perturbation. Responders exhibited increased abundance of taxa that were previously shown to be associated with response to anti-PD-1, increased CD8+ T cell activation, and decreased frequency of interleukin-8-expressing myeloid cells. Responders had distinct proteomic and metabolomic signatures, and transkingdom network analyses confirmed that the gut microbiome regulated these changes. Collectively, our findings show that FMT and anti-PD-1 changed the gut microbiome and reprogrammed the tumor microenvironment to overcome resistance to anti-PD-1 in a subset of PD-1 advanced melanoma.